UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): March 11, 2008
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
2
Elza Street
Jerusalem,
Israel 93706
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-54-790-9058
_____________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On
March
11, 2008, the registrant issued a press release announcing that it has
successfully completed Phase 1B clinical trials of its oral insulin capsule.
A
copy of the press release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(c)
|
Exhibits
|
|
|
99.1
|
Press
Release, dated March 11, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
Dated:
March 11, 2008
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and Director
|
Oramed
Pharmaceuticals Successfully Completes
Phase
1B Clinical Trials Of Oral Insulin Capsule
Phase
2A Trials Planned For Second Quarter 2008
JERUSALEM,
Israel - March 11, 2008 -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB
http://www.oramed.com), a developer of oral delivery systems, has successfully
completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B
trial, which utilized healthy volunteers, was focused on finding the optimal
dosage for the formulation of Oramed’s oral insulin product.
Oramed
plans to commence Phase 2A clinical trials in Israel in the second quarter
of
2008. The Phase 2A study is designed to evaluate the safety and efficacy of
Oramed’s oral insulin in Type II Diabetic volunteers. Oramed is simultaneously
working on completing the requirements for an IND for Phase 2 FDA approved
trials.
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is an Israeli-based company focused on the development
of
oral
delivery solutions based on proprietary technology. Diabetes is one of the
most
rapidly growing diseases in the world and is one that requires constant and
often
unpleasant monitoring and drug therapy regimens. Oramed is currently
developing
an orally ingestible insulin capsule for the treatment of diabetes. The
company
is also pursuing the development of oral delivery solutions for other drugs
and
vaccines.
For
more information please visit our website at: www.oramed.com.
Forward-looking
statements
Some
of
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company’s ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company’s filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements
Contact:
Oramed
Pharmaceuticals, Inc
Investor
Relations:
Erika
Moran
Public
Relations:
Lynn
Granito, Steve Melfi
212-825-3210
info@oramed.com
www.oramed.com